Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tritanrix-HepB/Hib-MenAC Safety and Reactogenicity in Healthy Infants
NCT00317135Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2003
- Primary completion
- Oct 2004
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Tritanrix-HepB/Hib-MenAC in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by GSK. Started Dec 2003; status: completed.
02
Drugs
Tritanrix-HepB/Hib-MenAC
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00317135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317135.